中国临床药理学杂志2018，Vol.34Issue(6)：611-614,4.DOI:10.13699/j.cnki.1001-6821.2018.06.001
替格瑞洛治疗急性冠状动脉综合征患者的临床研究
Clinical trial of ticagrelor in the treatment of patients with acute coronary syndrome
摘要
Abstract
Objective To investigate the clinical effect of long-term use of ticagrelor,and its effect on the levels of cardiac troponin T (cTnT),brain natriuretic peptide (BNP),C reactive protein (CRP),D-dimer (D-D) in patients with acute coronary syndrome.Methods Eighty-four patients with acute coronary syndrome were randomly divided into control group (42 cases) and treatment group (42 cases).Patients in two groups were given conventional treatment and symptomatic treatment.Patients were orally given aspirin 150 mg and clopidogrel 300 mg,1 time a day for 7 d,followed by percutaneous coronary intervention (PCI).After PCI surgery,patients in control group were given aspirin 100 mg,1 time a day,for6 months.Patients in treatment group were given aspirin 100 mg+ ticagrelor 90 mg,1 time a day,for 6 months.The clinical efficacy,acute heart attacks,duration of time,levels of ST segment depression,serum cTnT,BNP,CRP,D-D and adverse drug reactions were compared in two groups.Results After treatment,total effective rates in control group and treatment group were 78.57％ (33 cases/42 cases) and 95.24％ (40 cases/42 cases),with significant difference (P ＜0.05).The acute heart attacks in control and treatment groups were (4.52 ±0.55) and (2.02 ±0.27) time/ week.The duration of attacks were (4.14 ± 0.43) and (2.76 ± 0.31) min/time.The levels of ST segment depression were 1.25 ±0.17 and 0.63 ±0.07.There were significant difference between the two groups (P ＜0.05).After treatment,the levels of cTnT,CRP,BNP and D-D in control group were (1.54 ±0.18) ng · mL-1,(63.52 ±6.73) ng · mL-1,(8.94 ±0.94) mg · mL-1and (133.53 ± 15.73) ng · mL-1,had significant difference with those in treatment group,which were (0.25 ± 0.03) ng · mL-1,(28.43 ± 3.02) ng · mL-1,(4.57 ± 0.55)mg · mL-1,(59.54 ± 5.74) ng · mL-1 (P ＜ 0.05).The adverse drug reactions in control group were 2 cases of hea dache,2 cases of diarrhea,1 case of vomit,2 cases of dizziness,with the incidence of 16.67％ (7 cases/42 cases).The adverse drug reactions in treatment group were 1 case of gastrointestinal bleeding,1 case of elevated creatinine,1 case of dizziness,with the incidence of7.14％ (3 cases/42 cases).There was no significant difference between the two groups (P ＞ 0.05).Conclusion Long-term use of ticagrelor in the treatment of patients with acute coronary syndrome was effective with high safety.关键词
替格瑞洛/急性冠状动脉综合征/经皮冠状动脉介入术/肌钙蛋白T/脑钠素Key words
ticagrelor/acute coronary syndrome/percutaneous coronary intervention/cardiac troponin T/brain natriuretic peptide分类
医药卫生引用本文复制引用
张海龙..替格瑞洛治疗急性冠状动脉综合征患者的临床研究[J].中国临床药理学杂志,2018,34(6):611-614,4.基金项目
国家自然科学基金资助项目(81100073) （81100073）
